CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

SHARE TRANSACTION ACQUISITION OF 100% EQUITY INTEREST IN HYGIEIA INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2025

VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE III CLINICAL TRIAL OF TDI01 "ROCK2 INHIBITOR" FOR IDIOPATHIC PULMONARY FIBROSIS

VOLUNTARY ANNOUNCEMENT - TQH3906 “TYK2/JAK1 JH2 ALLOSTERIC INHIBITOR” ACHIEVING POSITIVE PROGRESS IN THE PHASE II CLINICAL TRIAL FOR PLAQUE PSORIASIS

VOLUNTARY ANNOUNCEMENT - "CULMERCICLIB CAPSULE" APPROVED FOR MARKETING

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQF3250 “ORALLY ADMINISTERED, BIASED GLP-1 RECEPTOR AGONIST” APPROVED BY THE NMPA AND FDA

VOLUNTARY ANNOUNCEMENT - “ROTIGOTINE PATCH” APPROVED FOR MARKETING